Our broad and diverse neuroscience pipeline includes five clinical-stage product candidates belonging to a new class of intranasal drugs called pherines. Each pherine product candidate in Vistagen’s neuroscience pipeline is designed to rapidly activate brain neurocircuitry through the olfactory system to achieve desired therapeutic benefits. Unlike oral, injectable, and other intranasal therapies, our neurocircuitry-focused pherines do not require systemic absorption (do not get into the bloodstream) or binding to neurons in the brain, which may contribute to favorable safety profiles.